Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Oscar Fernández, Miguel Angel Calleja-Hernández, José Meca-Lallana, Celia Oreja-Guevara, Ana Polanco & Ferran Pérez-Alcántara. (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics & Outcomes Research 17:4, pages 321-333.
Read now
Read now
Joan Vidal, John Slof, David Serrano, Teresa Marqués, Hatice Kumru & Jesús Benito-Penalva. (2017) Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 67-76.
Read now
Read now
Adrien Gras & Julie Broughton. (2016) A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 771-779.
Read now
Read now
K. Milinis & C. A. Young. (2016) Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions. Disability and Rehabilitation 38:15, pages 1431-1441.
Read now
Read now
Sven G Meuth, Carlos Vila & Kerry L Dechant. (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Review of Neurotherapeutics 15:8, pages 909-918.
Read now
Read now
John Slof, Leonardo Ruiz & Carlos Vila. (2015) Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Review of Pharmacoeconomics & Outcomes Research 15:3, pages 379-391.
Read now
Read now
Rafael Arroyo, Mariona Massana & Carlos Vila. (2013) Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. International Journal of Neuroscience 123:12, pages 850-858.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity epidemiology – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 45-46.
Read now
Read now
C. Oreja-Guevara, D. González-Segura & C. Vila. (2013) Spasticity in multiple sclerosis: results of a patient survey. International Journal of Neuroscience 123:6, pages 400-408.
Read now
Read now
Thomas Berger. (2013) Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Review of Neurotherapeutics 13:sup1, pages 3-7.
Read now
Read now
Nicolas Collongues & Patrick Vermersch. (2013) Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals. Expert Review of Neurotherapeutics 13:sup1, pages 21-25.
Read now
Read now
John Slof & Adrien Gras. (2012) Sativex® in multiple sclerosis spasticity: a cost–effectiveness model. Expert Review of Pharmacoeconomics & Outcomes Research 12:4, pages 439-441.
Read now
Read now
Derick Wade. (2012) Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?. Expert Review of Neurotherapeutics 12:sup4, pages 9-14.
Read now
Read now
Celia Oreja-Guevara. (2012) Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics 12:sup4, pages 3-8.
Read now
Read now
Articles from other publishers (26)
Yehuda Weizman, Oren Tirosh, Franz Konstantin Fuss, Adin Ming Tan & Erich Rutz. (2022) Recent State of Wearable IMU Sensors Use in People Living with Spasticity: A Systematic Review. Sensors 22:5, pages 1791.
Crossref
Crossref
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González & Lluís Ramió-Torrentà. (2021) Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. Frontiers in Neurology 12.
Crossref
Crossref
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, Anabel Estévez-Carrillo & Juan M. Ramos-Goñi. (2021) Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. The European Journal of Health Economics 22:5, pages 711-721.
Crossref
Crossref
Friedemann Paul & Carlos Vila Silván. (2021) Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref
Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler & Rachael L. Morton. (2017) Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics 36:1, pages 67-78.
Crossref
Crossref
Silvia Messina, Claudio Solaro, Isabella Righini, Roberto Bergamaschi, Simona Bonavita, Roberto Bruno Bossio, Vincenzo Brescia Morra, Gianfranco Costantino, Paola Cavalla, Diego Centonze, Giancarlo Comi, Salvatore Cottone, Maura Chiara Danni, Ada Francia, Alberto Gajofatto, Claudio Gasperini, Mauro Zaffaroni, Loredana Petrucci, Elisabetta Signoriello, Giorgia Teresa Maniscalco, Gabriella Spinicci, Manuela Matta, Massimiliano Mirabella, Graziella Pedà, Letizia Castelli, Marco Rovaris, Edoardo Sessa, Daniele Spitaleri, Damiano Paolicelli, Alfredo Granata, Mario Zappia & Francesco Patti. (2017) Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLOS ONE 12:8, pages e0180651.
Crossref
Crossref
G. Illomei, G. Spinicci, E. Locci & M. G. Marrosu. (2016) Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement. Neurological Sciences 38:3, pages 433-439.
Crossref
Crossref
F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino & M Zappia. (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery & Psychiatry 87:9, pages 944-951.
Crossref
Crossref
K. Milinis, A. Tennant & C.A. Young. (2016) Spasticity in multiple sclerosis: Associations with impairments and overall quality of life. Multiple Sclerosis and Related Disorders 5, pages 34-39.
Crossref
Crossref
Mar Tintoré. (2015) Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis. Neurodegenerative Disease Management 5:6s, pages 15-17.
Crossref
Crossref
Rainel Sánchez-de la Rosa, Laura García-Bujalance & José Meca-Lallana. (2015) Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review 5:1.
Crossref
Crossref
Jose Eustasio Meca‐Lallana, Rocío Hernández‐Clares & Ester Carreón‐Guarnizo. (2015) Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain and Behavior 5:9.
Crossref
Crossref
C. Lebrun & P. Vermersch. (2015) Une avancée pour la prise en charge de la spasticité dans la sclérose en plaques. Revue Neurologique 171:4, pages 327-328.
Crossref
Crossref
Patrick Vermersch. (2014) MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegenerative Disease Management 4:6, pages 407-415.
Crossref
Crossref
Thomas Henze, Sylvia von Mackensen, Gerald Lehrieder, Uwe K Zettl, Carmen Pfiffner & Peter Flachenecker. (2014) Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Uwe K. Zettl, Thomas Henze, Ute Essner & Peter Flachenecker. (2013) Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). The European Journal of Health Economics 15:9, pages 953-966.
Crossref
Crossref
Oleguer Parés-Badell, Gabriela Barbaglia, Petra Jerinic, Anders Gustavsson, Luis Salvador-Carulla & Jordi Alonso. (2014) Cost of Disorders of the Brain in Spain. PLoS ONE 9:8, pages e105471.
Crossref
Crossref
Rafael Arroyo, Carlos Vila & Kerry L Dechant. (2014)
Impact of Sativex
®
on quality of life and activities of daily living in patients with multiple sclerosis spasticity
. Journal of Comparative Effectiveness Research 3:4, pages 435-444.
Crossref
Crossref
Joanne M. Wagner, Theodore R. Kremer, Linda R. Van Dillen & Robert T. Naismith. (2014) Plantarflexor Weakness Negatively Impacts Walking in Persons With Multiple Sclerosis More Than Plantarflexor Spasticity. Archives of Physical Medicine and Rehabilitation 95:7, pages 1358-1365.
Crossref
Crossref
Theodore R. KremerLinda R. Van DillenJoanne M. Wagner. (2014) Dynamometer-based measure of spasticity confirms limited association between plantarflexor spasticity and walking function in persons with multiple sclerosis. Journal of Rehabilitation Research and Development 51:6, pages 975-984.
Crossref
Crossref
Jürgen Koehler. (2014) Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience. European Neurology 71:Suppl. 1, pages 10-15.
Crossref
Crossref
Carlo Pozzilli. (2014) Overview of MS Spasticity. European Neurology 71:Suppl. 1, pages 1-3.
Crossref
Crossref
J. Svensson, S. Borg & P. Nilsson. (2014) Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurologica Scandinavica 129:1, pages 13-20.
Crossref
Crossref
Helena Kupcova Skalnikova, Roman Navarro, Silvia Marsala, Rita Hrabakova, Petr Vodicka, Suresh Jivan Gadher, Hana Kovarova & Martin Marsala. (2013) Signaling proteins in spinal parenchyma and dorsal root ganglion in rat with spinal injury-induced spasticity. Journal of Proteomics 91, pages 41-57.
Crossref
Crossref
T. Henze, P. Flachenecker & U.K. Zettl. (2013) Bedeutung und Behandlung der Spastik bei Multipler SkleroseImportance and treatment of spasticity in multiple sclerosis. Der Nervenarzt 84:2, pages 214-222.
Crossref
Crossref